| Publisher’s Note: Break the silos. Spark the strategy. Fierce Pharma Engage brings every key function together to move brands forward. Learn how now! |
Today’s Big NewsApr 24, 2025 |
| By Nick Paul Taylor Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. |
|
|
|
By James Waldron Big Pharma M&A will likely take a hit if the U.S. government lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. |
By Gabrielle Masson Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. |
Sponsored by Fortrea Isagani (Gani) Chico, Vice President and Global Head of Oncology Therapeutic Expertise at Fortrea, shares how scientific advances, AI tools and flexible CRO models are accelerating oncology trials and improving patient outcomes. |
By James Waldron Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. |
By Nick Paul Taylor Bioxodes has stopped enrolling people in a phase 2a stroke study after hitting the safety and efficacy endpoints, positioning the Belgian biotech to power into a potentially registrational trial. |
By Darren Incorvaia A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ever getting seriously ill in the first place. |
By Fraiser Kansteiner Generic drug makers will be uniquely vulnerable if the Trump administration rolls out pharmaceutical tariffs, thanks to just how “little resilience” the industry enjoys compared to its patented counterpart, CEO of the United States Pharmacopeia, Ronald Piervincenzi, said in an interview. |
By Fraiser Kansteiner The FDA has slapped Empower Pharma with a warning letter citing a laundry list of production issues that put the company in violation of its 503B compounding credentials under the Federal Food, Drug, and Cosmetic Act. |
By Darren Incorvaia Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI. |
By Darren Incorvaia Bioengineering nonprofit Cultivarium is embarking on a three-year journey to develop tools and resources for scientists studying fungi and archaea, backed by $10 million in funding from the London-based foundation Wellcome Trust. |
By Noah Tong State provider taxes are under the spotlight in Medicaid and soon could be the subject of a proposed rule by the Centers for Medicare & Medicaid Services. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
